Teva stops selling migraine patches after reports of burns
Zecuity users told to stop applying device amid recall as pharmaceutical company works to figure out what's causing reactions
Teva Pharmaceutical said Monday that it will stop selling its migraine patch treatment Zecuity after users reported burns and scars where it was applied. The company advised that anyone who has its patch should not use it.
Zecuity is a disposable battery-powered patch that is worn on the upper arm or thigh once for four hours to ease migraine headaches. The patch delivers medicine through the skin.
The US Food and Drug Administration said some users reported severe redness, skin discoloration, cracked skin and pain where the patch was applied.
Teva, based in Israel, said it is recalling Zecuity from pharmacies and is working with the FDA to figure out what is causing the skin reactions.
The patch was approved by the FDA in 2013 when it was owned by NuPathe Inc. Teva bought NuPathe in 2014 and began selling Zecuity in the US late last year.
US-traded shares of Teva Pharmaceutical Industries Ltd. fell 2 cents to $52.99 in midday trading Monday.
Copyright 2016 The Associated Press.